| Quantity: | |
|---|---|
Topiroxostat is a selective xanthine oxidase inhibitor developed for treatment and management of hyperuricemia and gout. Xanthine oxidase, or xanthine oxidoreductase (XOR), regulates purine metabolism, and inhibition of the enzyme results in efficacious reduction of serum urate levels. Xanthine oxidase inhibitors are classified into two groups; purine analogs such as [DB00437] and [DB05262], and non-purine agents which includes topiroxostat. While [DB00437] is considered a first-line therapy in treating hyperuricemic conditions, it is often associated with side effects and ineffective in reducing uric acid levels under recommended dosing regimens. Renal complications are major comorbidities that limit the [DB00437] therapy as dose reductions are recommended. Topiroxostat and its metabolites are shown to be unaffected by renal complications, thus may be effective in patients with chronic kidney diseases.
Function
1.Xanthine Oxidase Inhibition: Topiroxostat selectively inhibits xanthine oxidase, an enzyme responsible for converting hypoxanthine and xanthine to uric acid. By blocking this enzyme, the conversion of these precursors into uric acid is decreased, resulting in a reduction of uric acid levels in the blood.
2.Treatment of Hyperuricemia in Gout: Gout is characterized by the deposition of urate crystals in the joints, leading to painful and inflammatory arthritis. Elevated levels of uric acid in the blood are a key factor in the development of gout. By lowering uric acid levels, Topiroxostat can help prevent the formation of urate crystals and reduce the frequency and severity of gout attacks.
Package
1kg/bag or 2kg/bag or 5kg/bag or 10kg/bag or according to customer’s requirements.
Topiroxostat is a selective xanthine oxidase inhibitor developed for treatment and management of hyperuricemia and gout. Xanthine oxidase, or xanthine oxidoreductase (XOR), regulates purine metabolism, and inhibition of the enzyme results in efficacious reduction of serum urate levels. Xanthine oxidase inhibitors are classified into two groups; purine analogs such as [DB00437] and [DB05262], and non-purine agents which includes topiroxostat. While [DB00437] is considered a first-line therapy in treating hyperuricemic conditions, it is often associated with side effects and ineffective in reducing uric acid levels under recommended dosing regimens. Renal complications are major comorbidities that limit the [DB00437] therapy as dose reductions are recommended. Topiroxostat and its metabolites are shown to be unaffected by renal complications, thus may be effective in patients with chronic kidney diseases.
Function
1.Xanthine Oxidase Inhibition: Topiroxostat selectively inhibits xanthine oxidase, an enzyme responsible for converting hypoxanthine and xanthine to uric acid. By blocking this enzyme, the conversion of these precursors into uric acid is decreased, resulting in a reduction of uric acid levels in the blood.
2.Treatment of Hyperuricemia in Gout: Gout is characterized by the deposition of urate crystals in the joints, leading to painful and inflammatory arthritis. Elevated levels of uric acid in the blood are a key factor in the development of gout. By lowering uric acid levels, Topiroxostat can help prevent the formation of urate crystals and reduce the frequency and severity of gout attacks.
Package
1kg/bag or 2kg/bag or 5kg/bag or 10kg/bag or according to customer’s requirements.
